Table 3. HIV-1 drug resistance mutations natural distribution of former paid blood donation population in Henan province.
| Number | Gender | Age | Drug Resistance Interpretation: PR | Drug Resistance Interpretation: RT | ||||||
| PI Maj | SpeR | PI Min | Spe R | NRTI | Spe R | NNRTI | Spe R | |||
| HNHIV1 | female | 53 | – | – | A71T | – | – | – | – | – |
| HNHIV3 | male | 51 | – | – | L10I | – | – | – | – | – |
| HNHIV4 | female | 46 | – | – | A71T | – | – | – | – | – |
| HNHIV6 | female | 36 | – | – | A71T | – | – | – | – | – |
| HNHIV10 | male | 50 | – | – | A71T | – | – | – | – | – |
| HNHIV13 | female | 37 | – | – | A71V | – | M184V | H:3TC,FTC L:ABC P:DDI | K103N, Y181C | H:EFV,NVP I:ETR,RPV |
| HNHIV15 | male | 57 | – | – | – | – | K70N | P:3TC,ABC,D4T,DDI,FTC,TDF | V108I | P:NVP |
| HNHIV19 | female | 49 | – | – | A71V | – | D67H, T69N, K70R, T215F, K219E | H:AZT,D4T I:DDI,TDF L:ABC | A98G, V179D, Y181C | H:NVP I:EFV,ETR,RPV |
| HNHIV20 | male | 56 | – | – | A71V | – | – | – | K103N | H:EFV,NVP |
| HNHIV23 | male | 46 | – | – | A71V | – | – | – | – | – |
| HNHIV24 | male | 54 | – | – | L10I | – | – | – | – | – |
| HNHIV26 | male | 49 | – | – | L10I, A71T | P:NFV | – | – | K103N, Y181C | H:EFV,NVP I:ETR,RPV |
| HNHIV29 | male | 37 | – | – | A71T | – | T215Y | I:AZT,D4T L:ABC,DDI,TDF | K103N | H:EFV,NVP |
| HNHIV36 | male | 51 | – | – | Q58E | P:TPV/r | – | – | – | – |
| HNHIV39 | male | 49 | – | – | A71V | – | – | – | K103N | H:EFV,NVP |
| HNHIV44 | male | 51 | – | – | A71V | – | – | – | – | – |
| HNHIV46 | male | 47 | – | – | A71V | – | D67N | L:AZT,D4T | K101E, G190A | H:NVP I:EFV L:ETR,RPV |
| HNHIV50 | male | 41 | – | – | L10I | – | – | – | – | – |
| HNHIV56 | male | 49 | – | – | A71T | – | – | – | – | – |
| HNHIV58 | male | 46 | – | – | A71T | – | – | – | – | – |
| HNHIV63 | male | 46 | – | – | A71V | – | – | – | – | – |
| HNHIV65 | female | 47 | – | – | – | – | – | – | K103N, Y181C | H:EFV,NVP I:ETR,RPV |
| HNHIV68 | male | 52 | – | – | – | – | – | – | K103N, Y181C | H:EFV,NVP I:ETR,RPV |
| Number | Gender | Age | Drug Resistance Interpretation: PR | Drug Resistance Interpretation: RT | ||||||
| PI Maj | SpeR | PI Min | Spe R | NRTI | Spe R | NNRTI | Spe R | |||
| HNHIV69 | male | 53 | – | – | – | – | – | – | K103N, Y181C | H:EFV,NVP I:ETR,RPV |
| HNHIV70 | male | 60 | – | – | – | – | – | – | K103N, V108I | H:EFV,NVP |
| HNHIV74 | male | 49 | – | – | A71T | – | – | – | – | – |
| HNHIV76 | male | 58 | – | – | – | – | – | – | K103N | H:EFV,NVP |
| HNHIV77 | male | 50 | – | – | A71V | – | – | – | K103N | H:EFV,NVP |
| HNHIV79 | female | 54 | – | – | – | – | M184L | – | – | – |
| HNHIV83 | female | 53 | – | – | A71T | – | – | – | – | – |
| HNHIV86 | male | 36 | – | – | – | – | – | – | V179E | – |
| HNHIV93 | female | 35 | – | – | A71V | – | D67H, T69N, K70R, T215F, K219E | H:AZT,D4T I:DDI,TDF L:ABC | A98G, V179D, Y181C | H:NVP I:EFV,ETR,RPV |
| HNHIV97 | male | 56 | – | – | – | – | D67N, T69A, K70R, T215Y, K219E | H:AZT,D4T I:TDF L:ABC,DDI | K103N, Y181C | H:EFV,NVP I:ETR,RPV |
| HNHIV100 | female | 47 | – | – | A71T | – | – | – | – | – |
| HNHIV113 | male | 30 | – | – | A71T | – | M41L, M184V, L210W, T215Y | H:3TC,ABC,AZT,D4T,DDI,FTC I:TDF | K103N, Y181C | H:EFV,NVP I:ETR,RPV |
| HNHIV114 | female | 39 | – | – | A71V | – | – | – | – | – |
| HNHIV116 | female | 54 | – | – | A71T | – | – | – | – | – |
| HNHIV121 | male | 36 | – | – | A71T | – | – | – | – | – |
| HNHIV137 | male | 49 | – | – | A71V | – | D67N | L:AZT,D4T | K101E, G190A | H:NVP I:EFV L:ETR,RPV |
| HNHIV139 | male | 51 | – | – | L10I | – | – | – | – | – |
| HNHIV145 | male | 40 | – | – | A71T | – | – | – | – | – |
| HNHIV149 | female | 52 | – | – | A71T | – | – | – | – | – |
| HNHIV150 | male | 48 | – | – | – | – | – | – | V179E | – |
PI mar, PI Major Resistance Mutations; PI min, PI Minor Resistance Mutations; Spe R, Specific resistance; H, High-level resistance; I, Intermediate resistance; L, Low-level resistance; P, Potential low-level resistance; ATV/r, atazanavir/r; DRV/r, darunavir/r; FPV/r, fosamprenavir/r; IDV/r, indinavir/r; LPV/r, lopinavir/r; NFV, nelfinavir; SQV/r, saquinavir/r; TPV/r, tipranavir/r; 3TC, lamivudine; ABC, abacavir; AZT, zidovudine; D4T, stavudine; DDI, didanosine; FTC, emtricitabine; TDF, tenofovir; EFV, efavirenz; ETR, etravirine; NVP, nevirapine; RPV, rilpivirine; Mutation sites according to the area of the amino acid position in the form of so-called “M184V” records, said sharing sequence of RT’s 184th “M” was replaced by “V”.